Solid Tumors Clinical Trial
Official title:
A Phase I Dose-Escalation Study of Erlotinib in Combination With Pralatrexate in Subjects With Advanced Cancer
The goal of this clinical research study is to find the highest tolerable dose of the
combination of erlotinib and pralatrexate that can be given to patients with advanced
cancer. The safety of the drug combination will also be studied.
Pralatrexate is designed to block the body's ability to make folic acid, a protein that may
help cancer tissue to develop and spread.
Erlotinib hydrochloride is designed to block proteins that are thought to cause cancer cells
to grow. Erlotinib may help slow the growth of tumors.
Study Groups:
If you are found to be eligible to take part in this study, you will be assigned to a dose
level of erlotinib and pralatrexate based on when you join this study.
Dose Escalation:
Several dose levels of erlotinib and pralatrexate will be tested. Three (3) to 6
participants will start at the lowest planned doses of erlotinib and pralatrexate. Each new
group of 3-6 participants will receive a higher dose than the group before it, if no
intolerable side effects were seen. This will continue until the highest tolerable dose of
erlotinib in combination with pralatrexate is found.
Dose Expansion:
Once the highest tolerable dose or most appropriate combination dose level is found, 10 more
participants will take the study drugs at this dose level.
Study Drug Administration:
Each study cycle is 28 days.
Up to 10 days before you start treatment , you will start taking folic acid to help lower
the risk of side effects. Although the study drug is designed to prevent the body from
making folic acid that could help cancer grow and spread, some folic acid is needed to
prevent side effects in non-cancerous tissue. You will take folic acid by mouth 1 time every
day during treatment and for at least 30 days after you received the last dose of
pralatrexate.
Up to 10 days before you start treatment, you will receive a vitamin B12 injection. You will
receive an injection of Vitamin B12 about every 3 months after that.
On Days 1, 8, and 15 of each cycle, you will receive pralatrexate by vein over 3-5 minutes.
You will take erlotinib hydrochloride by mouth 1 time a day every day. You should take
erlotinib hydrochloride on an empty stomach either 1 hour before eating or 2 hours after
eating.
You will take erlotinib at home except on the days when you have a study visit. You should
take it at about the same time each day with about a cup (8 ounces) of water.
Study Visits:
At every study visit, you will be asked about any current health conditions you have, any
other drugs you are taking, and if you have had any side effects.
If the screening tests were performed within 7 days before Cycle 1, tests and procedures may
not have to be repeated.
At any time during Cycle 1:
- You will have a physical exam, including measurement of your weight at least 1 time per
cycle.
- Your vital signs will be measured.
- Your performance status will be recorded.
- Blood (about 2 teaspoons) will be drawn for routine tests and to see how well your
blood clots.
- If you are taking part in the expansion phase, blood (about 2 teaspoons) will be drawn
for pharmacodynamic (PD) testing.
At any time during Cycle 2:
- You will have a physical exam, including measurement of your weight at least 1 time per
cycle.
- Your vital signs will be measured.
- Your performance status will be recorded.
- Blood (about 4 teaspoons) will be drawn for routine tests.
- If you are taking part in the expansion phase, blood (about 2 teaspoons) will be drawn
for PD testing.
About every 8 weeks, you will have an x-ray, CT scan, MRI scan, and/or positron emission
computed tomography (PET)/CT scan to check the status of the disease. Blood (about 1
teaspoon) may be drawn for tumor marker testing depending on the type of tumor. If the study
doctor thinks it is needed, they will be performed more or less often.
At any time during Cycle 3 and beyond:
- You will have a physical exam, including measurement of your weight at least 1 time per
cycle.
- Your vital signs will be measured.
- Your performance status will be recorded.
- Blood (about 2 teaspoons) will be drawn for routine tests.
Length of Dosing:
You may continue taking the study drugs for as long as the doctor thinks it is in your best
interest. You will no longer be able to take the study drugs if the disease gets worse, if
intolerable side effects occur, or if you are unable to follow study directions.
Your participation on the study will be over once you have completed the end-of-treatment
and follow-up visits.
End of Dosing Visit:
After you are finished taking the study drugs:
- You will have a physical exam, including measurement of your weight and vital signs.
- Your performance status will be recorded.
- Blood (about 2 teaspoons) and urine will be collected for routine tests.
This is an investigational study. Pralatrexate is FDA approved and commercially available
for the treatment of cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma (PTCL).
Erlotinib is FDA approved and commercially available for the treatment of pancreatic cancer
and non small cell lung cancer (NSCLC). The study drug combination is investigational.
Up to 74 patients will take part in this study. All will be enrolled at MD Anderson.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT00750841 -
Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours
|
Phase 1 | |
Withdrawn |
NCT05419817 -
Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System
|
Phase 2 | |
Completed |
NCT02828930 -
A Study to Determine the Excretion Balance, Pharmacokinetics, Metabolism and Absolute Oral Bioavailability of a Single Oral Dose of [14C]-Labeled Idasanutlin and an Intravenous Tracer Dose of [13C]-Labeled Idasanutlin in a Single Cohort of Participants With Solid Tumors (Malignancies)
|
Phase 1 | |
Completed |
NCT01197170 -
Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance
|
Phase 1 | |
Completed |
NCT03258515 -
A Study to Investigate the Effect of Single Dose of AZD6094 (600 mg) on Cardiac Repolarization in Healthy Volunteers
|
Phase 1 | |
Terminated |
NCT03225105 -
M3541 in Combination With Radiotherapy in Solid Tumors
|
Phase 1 | |
Completed |
NCT01497925 -
Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer
|
Phase 1 | |
Completed |
NCT01878890 -
Phase I Dose Escalation Trial of Efavirenz in Solid Tumours or Non-Hodgkin Lymphoma in Therapeutic Failure.
|
Phase 1 | |
Active, not recruiting |
NCT05059522 -
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
|
Phase 3 | |
Active, not recruiting |
NCT03634982 -
Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors
|
Phase 1 | |
Recruiting |
NCT04685226 -
A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
Recruiting |
NCT06036121 -
A Study of ADRX-0706 in Select Advanced Solid Tumors
|
Phase 1 | |
Active, not recruiting |
NCT03258151 -
Association of Genetic Polymorphisms With Docetaxel-based Chemotherapy Toxicities in Chinese Solid Tumor Patients
|
||
Completed |
NCT01528046 -
Metformin in Children With Relapsed or Refractory Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05325866 -
A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
|
Phase 1/Phase 2 | |
Recruiting |
NCT04557449 -
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
|
Phase 1/Phase 2 | |
Terminated |
NCT02890368 -
Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides
|
Phase 1 | |
Completed |
NCT02759640 -
A Phase I Trial of HS-10241 in Solid Tumors
|
Phase 1 | |
Withdrawn |
NCT01940601 -
Pharmacodynamics, Pharmacokinetics, Efficacy and Safety of Balugrastim in Pediatric Patients With Solid Tumors
|
Phase 2 |